TWiV 1070: Clinical update with Dr. Daniel Griffin

This Week in Virology - Un pódcast de Vincent Racaniello

Categorías:

In his weekly clinical update, Dr. Griffin discusses monkeypox and chickenpox co-infection in southern Nigeria, vaccine effectiveness against influenza A, SARS-CoV-2 neutralizing antibody titers in maternal blood, umbilical cord blood, and breast milk, COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens, four methods for monitoring SARS-CoV-2 and Influenza A virus activity in schools, efficacy and safety of Baricitinib for the treatment of hospitalized adults with COVID-19, a synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong, consistent absence of cerebrospinal fluid biomarker abnormalities in patients with neurocognitive post-COVID complications, and risk of new-onset long COVID following reinfection with SARS-CoV-2. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Monkeypox and chickenpox co-infection in southern Nigeria (JID) Vaccine effectiveness against influenza A (CID) SARS-CoV-2 neutralizing antibody titers in maternal blood, umbilical cord blood, and breast milk (JOP) COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens (JAMA) Four methods for monitoring SARS-CoV-2 and influenza A virus activity in schools (JAMA) Efficacy and safety of Baricitinib for the treatment of hospitalized adults with COVID-19 (EJMR) A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (The Lancet) Consistent absence of cerebrospinal fluid biomarker abnormalities in patients with neurocognitive post-COVID complications (JID) Risk of new-onset long COVID following reinfection with SARS-CoV-2 (OFID) Contribute to our MicrobeTV fundraiser at PWB Dr. Griffin’s COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

Visit the podcast's native language site